First Patient Dosed in Phase 1/2 Trial of FLX475 in Breast, Other Advanced Cancers

First Patient Dosed in Phase 1/2 Trial of FLX475 in Breast, Other Advanced Cancers
The first patient has been dosed in a Phase 1/2 trial evaluating FLX Bio’s investigational therapy, FLX475, alone and in combination with the PD-1 inhibitor Keytruda (pembrolizumab), as a therapy for triple negative breast cancer and other advanced cancers. The study (NCT03674567) is recruiting participants at cancer centers in the United States, Australia, and Asia, and is expected to include 375 patients. “The dosing of our first patient with FLX475 is a significant milestone for FLX Bio as we continue to advance our novel therapeutic approach targeting the tumor microenvironment,” Brian Wong, MD, PhD, CEO of FLX Bio, said in a press release. FLX475 is an oral, small inhibitor of the C-C chemokine receptor 4 (CCR4), a receptor protein predominantly found at the surface of regulatory T-cells, or Tregs. Tregs are a group of cells of the immune system whose function is to keep immune responses in check and prevent other immune cells from attacking the body's own tissues (a condition known as autoimmunity). But Tregs can also accumulate inside and around tumors to suppress the immune system’s response. This trafficking of Tregs into the tumor mass is
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.